Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
نویسندگان
چکیده
The release of endogenous prostacyclin (PGI2) is depressed in patients with pulmonary arterial hypertension (PAH). PGI2 replacement therapy by epoprostenol infusion is one of the best treatments available for PAH. Here, we provide an overview of the current clinical data for epoprostenol. Epoprostenol treatment improves symptoms, exercise capacity, and hemodynamics, and is the only treatment that has been shown to reduce mortality in patients with idiopathic PAH (IPAH) in randomized clinical trials. We have reported that high-dose epoprostenol therapy (>40 ng/kg/min) also results in marked hemodynamic improvement in some patients with IPAH. High-dose epoprostenol has a pro-apoptotic effect on PAH-PASMCs via the IP receptor and upregulation of Fas ligand (FasL) in vitro. However, long-term intravenous administration of epoprostenol is sometimes associated with catheter-related infections and leads to considerable inconvenience for the patient. In the future, the development of new routes of administration or the development of powerful PGI2 analogs, IP-receptor agonists, and gene and cell-based therapy enhancing PGI2 production with new routes of administration is required.
منابع مشابه
Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
INTRODUCTION Pulmonary arterial hypertension (PAH) is associated with poor prognosis despite significant recent advances in its treatment. An intravenous formulation of epoprostenol sodium containing glycine and mannitol (epoprostenol GM; GlaxoSmithKline, London, UK) is widely used to treat PAH. A new formulation of epoprostenol sodium containing arginine and sucrose excipients (epoprostenol AS...
متن کاملErratum to: Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with a Pulmonary Arterial Hypertension (EPITOME4)
متن کامل
Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted
PURPOSE Epoprostenol, used for the treatment of pulmonary arterial hypertension (PAH), has a number of limitations related to its short half-life in aqueous solution. The aim of this study was to evaluate the stability and microbiological properties of a new formulation, namely epoprostenol sodium with arginine and mannitol excipients (epoprostenol AM; Veletri®; Actelion Pharmaceuticals Ltd, Al...
متن کامل5.01.522 Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension
The following therapies may be considered medically necessary for the treatment of pulmonary arterial hypertension (PAH/ WHO Group 1): ambrisentan (LETAIRIS®) oral; bosentan (TRACLEER®) oral; epoprostenol sodium (e.g., FLOLAN®) continuous IV infusion; Iloprost (VENTAVIS®) Inhalation via nebulizer; macitentan (OPSUMIT®) oral; riociguat (ADEMPAS®) oral; sildenafil citrate (e.g., REV...
متن کامل5.01.522 Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension
The following therapies may be considered medically necessary for the treatment of pulmonary arterial hypertension (PAH/ WHO Group 1): ambrisentan (LETAIRIS®) oral; bosentan (TRACLEER®) oral; epoprostenol sodium (e.g., FLOLAN®) continuous IV infusion; Iloprost (VENTAVIS®) Inhalation via nebulizer; macitentan (OPSUMIT®) oral; riociguat (ADEMPAS®) oral; sildenafil citrate (e.g., REV...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 6 شماره
صفحات -
تاریخ انتشار 2012